Scientist/Senior Scientist, Vascular at NewLimit

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
Experience with primary endothelial cell isolation and functional characterization
Experience working with mouse models of endothelial cell function (e.g. kidney, cardiovascular, or cognitive disease models)
Experience with transgenic manipulation of endothelial cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery)

Responsibilities

Develop functional assays and pre-clinical models to measure endothelial cell function
Collaborate with our Functional Genomics and Predictive Modeling teams to test reprogramming hypotheses at scale
Measure the impact of mRNA reprogramming medicines on endothelial cell function
Engineer in vivo nucleic acid delivery methods for endothelial cells
Analyze and interpret experimental data to drive pre-clinical decision making

Skills

Key technologies and capabilities for this role

Endothelial Cell IsolationFunctional AssaysMouse ModelsViral VectorsNucleic Acid DeliverymRNA ReprogrammingPre-clinical ModelsFunctional GenomicsData AnalysisTransgenic Manipulation

Questions & Answers

Common questions about this position

What qualifications are required for the Scientist/Senior Scientist, Vascular position?

A Ph.D. in cell biology, molecular biology, biochemistry or a related field, or equivalent industry experience with 5+ years is required. Key experiences include primary endothelial cell isolation and functional characterization, working with mouse models of endothelial cell function, and transgenic manipulation of endothelial cells ex vivo or in vivo.

What are the main responsibilities in this role?

Responsibilities include developing functional assays and pre-clinical models for endothelial cell function, collaborating with Functional Genomics and Predictive Modeling teams, measuring impacts of mRNA reprogramming medicines, engineering in vivo nucleic acid delivery methods, and analyzing data for pre-clinical decisions.

What 'nice to have' experiences are mentioned for this position?

Preferred experiences include contributing to drug development programs at pre-clinical or clinical stages, leading pre-clinical studies in mouse models, single cell genomics methods, and pooled screening approaches like CRISPR fitness screens or Perturb/CROP-seq.

Is the salary or compensation specified for this role?

This information is not specified in the job description.

What kind of work arrangement or location is required?

This information is not specified in the job description.

NewLimit

Medicines for healthspan extension via epigenetics

About NewLimit

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance health during aging. The company serves the healthcare market, working with pharmaceutical companies and healthcare providers, and aims to transform aging by developing effective treatments.

South San Francisco, CaliforniaHeadquarters

2022Year Founded

$38.9MTotal Funding

SERIES_ACompany Stage

Biotechnology, HealthcareIndustries

11-50Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Risks

Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.

Ethical concerns and regulatory scrutiny may delay product approvals.

Competition from similar biotech firms could impact NewLimit's market share.

Differentiation

NewLimit focuses on epigenetic reprogramming to extend human healthspan.

The company uses single-cell genomics and machine learning for drug discovery.

NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Upsides

Increased interest in epigenetic reprogramming boosts NewLimit's market potential.

Machine learning aids in identifying novel drug candidates for age-related diseases.

FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

Land your dream remote job 3x faster with AI

Try Jobo Free